Transchem

Who are the top shareholders of the Transchem?

The top shareholders of Transchem are Priyanka Finance Private Limited with 40.11%, followed by Smit Capital Services Private Limited at 11.02%. Individual investors own 24.69%, with no pledged promoter holdings or shares held by mutual funds or foreign institutional investors.

The top shareholders of Transchem include Priyanka Finance Private Limited, which holds the largest stake at 40.11%. Following that, Smit Capital Services Private Limited is the highest public shareholder with an 11.02% ownership. Additionally, individual investors collectively hold 24.69% of the company's shares. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares.

Who are in the management team of Transchem?

As of March 2023, the management team of Transchem includes Bina Shah (Chairperson), Neerav Merchant (Independent Director), Neeraja Karandikar (Company Secretary & Compliance Officer), Mirza Saeed Kazi (Director), and Mahesh Suresh Rananavre (Whole-time Director). Each member contributes to the company's governance and operations.

As of March 2023, the management team of Transchem includes the following individuals:<BR><BR>1. Bina Shah - Chairperson<BR>2. Neerav Merchant - Independent Director<BR>3. Neeraja Karandikar - Company Secretary & Compliance Officer<BR>4. Mirza Saeed Kazi - Director<BR>5. Mahesh Suresh Rananavre - Whole-time Director<BR><BR>Each member plays a crucial role in the governance and operational oversight of the company.

What does Transchem do?

Transchem Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, focusing on mushroom production and processing, as well as chemicals and pharmaceuticals. As of March 2025, it reported net sales of 2 Cr and a net profit of 1 Cr, with a market cap of Rs 49 Cr.

Overview: <BR>Transchem Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, primarily engaged in the production and processing of mushrooms along with dealing in chemicals and pharmaceuticals.<BR><BR>History: <BR>Transchem Ltd was incorporated as a private limited company in 1976 and converted into a public limited company in 1992. The company diversified its activities in 1993 to focus on mushroom production and processing. The latest quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 2 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 49 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 9.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.00 <BR>Return on Equity: 6.75% <BR>Price to Book: 0.63 <BR><BR>Contact Details: <BR>Address: 304 Ganatra Estate, Pokhran Road No.1 Khopat Thane (West) Maharashtra : 400601 <BR>Tel: 91-22-25477077 <BR>Email: secretaryu@transchem.net <BR>Website: http://www.transchem.net

Has Transchem declared dividend?

No Dividend History Available

Who are the peers of the Transchem?

Transchem's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Shelter Pharma, Chandra Bhagat, Vista Pharma, and Medicamen. Transchem has average management risk, below average growth, and a 1-year return of 7.69%, compared to its peers' varying performance.

Peers: The peers of Transchem are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Shelter Pharma, Chandra Bhagat, Vista Pharma., and Medicamen.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Shelter Pharma, while Good management risk is found at Divi's Lab., Torrent Pharma, and Medicamen. Average management risk is noted for Transchem, and Below Average management risk is present at Chandra Bhagat and Vista Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Medicamen, while Below Average growth is seen at Transchem, Torrent Pharma, Chandra Bhagat, and Vista Pharma. Finally, Excellent capital structure is noted for Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Shelter Pharma, while Below Average capital structure is found at Transchem, Chandra Bhagat, and Medicamen.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Chandra Bhagat has the lowest at -42.15%. Transchem's 1-year return is 7.69%, which is significantly lower than Divi's Lab. and higher than Chandra Bhagat. Additionally, the six-month return is negative for Shelter Pharma, Chandra Bhagat, Vista Pharma., and Transchem.

Is Transchem overvalued or undervalued?

As of April 25, 2023, Transchem is considered a risky but undervalued investment with favorable valuation metrics, including a PE Ratio of 9.28, compared to its peers, despite recent underperformance against the Sensex.

As of 25 April 2023, the valuation grade for Transchem has moved from does not qualify to risky. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 9.28, a Price to Book Value of 0.63, and a PEG Ratio of 0.39, indicating potential for growth relative to its price. <BR><BR>In comparison to its peers, Transchem's valuation appears favorable against Sun Pharma's PE Ratio of 35.25 and Divi's Lab's PE Ratio of 79.33, both of which are classified as expensive. Additionally, Transchem's EV to EBITDA ratio of -32.72 stands out as a notable outlier, suggesting significant challenges in profitability relative to its enterprise value. Despite recent underperformance against the Sensex, with a year-to-date return of -22.30% compared to the Sensex's 5.59%, the overall valuation metrics suggest that Transchem may present an attractive opportunity for investors.

What is the technical trend for Transchem?

As of June 2, 2025, Transchem's technical trend has shifted to mildly bearish, influenced by daily moving averages and weekly Bollinger Bands indicating bearish conditions, despite some mildly bullish signals from the weekly MACD and KST.

As of 2 June 2025, the technical trend for Transchem has changed from sideways to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also signaling bearish conditions. While the weekly MACD and KST are mildly bullish, they are offset by the overall bearish indicators. The stock has experienced a significant decline year-to-date, further supporting the bearish outlook.

How big is Transchem?

As of 24th July, Transchem Ltd has a market capitalization of 54.00 Cr, with Net Sales of 2.63 Cr and a Net Profit of 5.22 Cr reported in the latest four quarters. Shareholder's Funds are 75.65 Cr and Total Assets are 76.32 Cr as of March 2024.

As of 24th July, Transchem Ltd has a market capitalization of 54.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Transchem reported Net Sales of 2.63 Cr and a Net Profit of 5.22 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 75.65 Cr and Total Assets at 76.32 Cr.

When is the next results date for Transchem?

Transchem will declare its results on 07 August 2025.

Transchem will declare its results on 07 August 2025.

Are Transchem latest results good or bad?

Transchem's latest results are concerning, showing a 52.78% decline in net profit year-over-year and zero sales revenue, indicating significant operational challenges. The company's reliance on investment income and poor return on equity further highlight its unsustainable financial health.

Transchem's latest results can be considered concerning. In Q2 FY26, the company reported a net profit of ₹0.68 crores, which is a significant decline of 52.78% year-over-year and 31.31% quarter-over-quarter. Notably, the company generated zero sales revenue during this quarter, continuing a troubling trend of no operating revenue, which raises serious questions about its business viability.<BR><BR>The operating profit, excluding other income, was negative at ₹0.74 crores, marking the worst performance in twelve quarters. This indicates that the company is not only failing to generate revenue from its core pharmaceutical operations but is also incurring operational losses.<BR><BR>Transchem's reliance on investment income is evident, as it constituted 180.65% of profit before tax in Q2 FY26. This heavy dependence on non-operating income is unsustainable and poses risks to the company's financial health. Furthermore, the return on equity of 5.74% is significantly below industry standards, reflecting poor capital efficiency.<BR><BR>While the stock has performed well in terms of price appreciation, gaining 32.45% over the past year, this performance is disconnected from the underlying business fundamentals. Overall, the results highlight a critical situation for Transchem, with no clear path to reviving its pharmaceutical operations or establishing a viable business model.

How has been the historical performance of Transchem?

Transchem's historical performance shows significant growth, with net sales and total operating income reaching 2.63 Cr in March 2025, up from 0.41 Cr in March 2024. Despite increased expenditures, the company reported improved profits, with profit after tax rising to 5.23 Cr and a net cash inflow of 42 Cr, indicating a positive trend in revenue and profitability.

Answer:<BR>The historical performance of Transchem shows a significant increase in net sales, reaching 2.63 Cr in March 2025, up from 0.41 Cr in March 2024, and starting from zero in previous years. Total operating income also rose to 2.63 Cr in March 2025, reflecting the same trend. However, total expenditure increased to 4.09 Cr in March 2025, leading to an operating profit (PBDIT) of 7.07 Cr, which is an improvement from 5.67 Cr in March 2024. The profit before tax for March 2025 was 7.06 Cr, up from 5.65 Cr in the prior year, while profit after tax reached 5.23 Cr, compared to 4.20 Cr in March 2024. The earnings per share (EPS) increased to 4.27 in March 2025 from 3.43 in March 2024. <BR><BR>In terms of assets and liabilities, total assets grew to 79.73 Cr in March 2025, up from 76.32 Cr in March 2024, with total liabilities also increasing to 79.73 Cr. The company maintained a stable equity capital of 12.24 Cr across the years. Cash flow from operating activities improved significantly to 36 Cr in March 2025, compared to a negative 39 Cr in March 2024, contributing to a net cash inflow of 42 Cr in March 2025, a notable recovery from a net outflow of 34 Cr in the previous year. Overall, Transchem's financial performance indicates a positive trend in revenue generation and profitability, despite rising expenditures.<BR><BR>Breakdown:<BR>Transchem's financial performance has shown a remarkable upward trajectory in net sales, which surged to 2.63 Cr in March 2025 from 0.41 Cr in March 2024, marking a significant recovery from previous years where sales were non-existent. Total operating income mirrored this growth, reaching 2.63 Cr in March 2025. Despite the increase in total expenditure to 4.09 Cr, the company reported an operating profit (PBDIT) of 7.07 Cr, up from 5.67 Cr in the prior year, indicating improved operational efficiency. Profit before tax also rose to 7.06 Cr, while profit after tax reached 5.23 Cr, reflecting a healthy increase from 4.20 Cr in March 2024. The earnings per share (EPS) rose to 4.27, further showcasing the company's profitability. On the balance sheet, total assets increased to 79.73 Cr, with total liabilities matching this figure, indicating a stable financial position. Cash flow from operating activities saw a significant turnaround, resulting in a net cash inflow of 42 Cr in March 2025, a stark contrast to the previous year's outflow. Overall, Transchem's financial metrics indicate a positive trend in both revenue and profitability, despite rising costs.

Should I buy, sell or hold Transchem?

Why is Transchem Ltd falling/rising?

As of 18-Jan, Transchem Ltd's stock price is rising to 172.15, marking a trend reversal after seven days of decline and outperforming its sector. Despite impressive long-term returns, the company faces financial challenges that could affect future performance.

As of 18-Jan, Transchem Ltd's stock price is rising, currently at 172.15, reflecting a change of 3.35 (1.98%) upward. This increase is notable as it marks a trend reversal after seven consecutive days of decline. The stock has outperformed its sector by 3.09% today, indicating a positive shift in investor sentiment.<BR><BR>Despite the recent rise, it is essential to consider the broader context of the company's performance. Over the past year, Transchem Ltd has delivered impressive returns of 292.23%, significantly outperforming the Sensex, which only gained 8.47% in the same period. Additionally, the stock has shown remarkable growth over three and five years, with returns of 536.41% and 806.05%, respectively. <BR><BR>Today's trading activity also reflects increased investor participation, with delivery volume rising by 1849.78% compared to the five-day average, suggesting heightened interest in the stock. However, it is important to note that the company faces challenges, including operating losses and weak long-term fundamental strength, which could impact future performance. The company's operating profit growth has been modest at an annual rate of 3.88% over the last five years, and it has reported negative earnings before interest, taxes, depreciation, and amortization (EBITDA).<BR><BR>In summary, while Transchem Ltd's stock is currently rising due to a trend reversal and strong historical performance, underlying financial challenges remain a concern for investors.

Which are the latest news on Transchem?